United States also proposes that the Consent Judgment be amended to permit ASCAP to collect home taping royalties collected by foreign performing rights societies on behalf of ASCAP members. The proposed modifications have no effect on other provisions of the Consent Judgment, which will remain in effect: (1) Requiring ASCAP to hold musical performing rights on a non-exclusive basis; and, (2) prohibiting ASCAP from interfering with an ASCAP member's right to license directly.

The United States has filed with the Court a memorandum setting forth the reasons why it believes that modification of the Consent Judgment serves the public interest. Copies of the United States' application to Modify the Consent Judgment, Memorandum in Support, Stipulation and Order, and proposed Order Modifying the Consent Judgment, and all further papers filed with the Court in connection with this motion will be available for inspection at Room 200, Antitrust Division, Department of Justice, 325 Seventh Street, NW., Washington DC 20530, (202.514.2481), and at the Office of the Clerk of the United States District Court for the Southern District of New York, 300 Quarropas Street, White Plains, New York 10601–4150. Copies of any of these materials may be obtained from the Antitrust Division upon request and payment of the copying fee set by Department of Justice regulations.

Interested persons may submit comments regarding the proposed modification of the consent judgment to the Department of Justice, Antitrust Division. Such comments must be received by the Division within sixty (60) days and will be filed with the court. Comments should be addressed to Mary Jean Moltenbrey, Antitrust Division, Department of Justice, 325 Seventh Street, NW., Room 300, Washington, DC 20530 (202.616.5935).

Rebecca P. Dick,

Deputy Director of Operations.

[FR Doc. 97–21235 Filed 8–11–97; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993: Appliance Industry—Government CFC Replacement Consortium

Notice is hereby given that, on June 27, 1997, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. § 4301 *et seq.* (''the Act''), The Appliance Industry-Government CFC Replacement Consortium, Inc. (''Corporation'') filed notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its participants' status. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, the following have become additional participants of the Corporation: Marvel Industries, a division of Northland Corporation, Richmond, IN; Goldschmidt Chemical Company, Hopewell, VA; Air Products & Chemicals, Elburn, IL; and Witco Corporation, Greenwich, CT. In addition, Bayer Corporation, Pittsburgh, PA has acquired the styrenics business unit of Monsanto Corporation, Springfield, MA (effective January 3, 1996), with Bayer Corporation being the sole surviving corporation. As a request of the acquisition, the rights and obligations of Monsanto as a participant in the Corporation have been transferred to Bayer as of that date.

No other changes have been made in either the membership or planned activity of the Corporation.

On September 19, 1989, the Corporation filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on November 1, 1989 (54 FR 46136).

The last notification was filed with the Department on July 1, 1993. A notice was published in the **Federal Register** on August 17, 1993 (58 FR 43655).

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 97–21232 Filed 8–11–97; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1933—ECC Development Program

Notice is hereby given that, on June 27, 1997, pursuant to § 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. § 4301 *et seq.* (''the Act''), ECC Development Program (the ''Program'') has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recorder of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to § 6(b) of the Act, the identities of the parties are: Cygnus Solutions, Sunnyvale, CA; Matsushita Electronics Corporation, Nagaokakyo, Kyoto 617, Japan; Toshiba Corporation, Kanagwa-ken 210, Japan; Cisco Systems, Inc., San Jose, CA.

The ECC Development Program's area of planned activity is to develop and promote open standard technologies for embedded software. The ECC Development Program hopes to contribute to the growth of microncontrollers and industries that depend on microcontrollers. The ECC Development Program participants plan to engage in all necessary activities to accomplish the goal and objectives described above, including without limitation: (1) Developing and refining software specifications; (2) conducting cooperative research on and testing these specifications, (3) publishing and certifying these specifications; (4) disseminating these specifications to interested parties for their use in designing and producing compatible products; (5) developing publications and informational materials relating to the activities of this Program; and (6) engaging in other activities to promote the technology.

Membership in the ECC Development Program will remain open and ECC will file additional written notifications disclosing all changes in membership.

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 97–21234 Filed 8–11–97; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Financial Services Technology Consortium, Inc.

Notice is hereby given that, on June 25, pursuant to § 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. § 4301 *et seq.* (''the Act''), the Financial Services Technology Consortium, Inc. (''Consortium''), has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership and area of planned

activity. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Specifically, the membership changes are as follows: Norwest Corporation, Minneapolis, MN was admitted as a principal member. Compaq Computer Corporation, Houston, TX and @Work Technologies, New York, NY were admitted as Associate Members. American Recovery Association, New Orleans, LA was admitted as an Advisory Member. The following parties are no longer members; Equifax Credit Information Services; Global Concepts, Inc.; Gemini Computers, Inc.; Raptor Systems, Inc.; SSDS, Inc.; Home Financial Network, Inc.; and YCS, Inc. Membership remains open and the Consortium intends to file additional written notifications disclosing all changes in membership.

The consortium also filed notice that it has entered into an Agreement for Strategic Alliance with the Banking Industry Technology Secretariat (''BITS'') as a new activity of the Consortium.

On October 21, 1993, the Financial Services Technology Consortium filed its original notification pursuant to § 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to § 6(b) of the Act on December 14, 1993 (58 FR 65399). The last notification was filed on February 6, 1997. A notice was published in the **Federal Register** on March 20, 1997 (62 FR 13394).

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 97–21233 Filed 8–11–97; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By Notice dated March 12, 1997, and published in the **Federal Register** on March 19, 1997, (62 FR 13169), Glaxo Wellcome Inc., Attn: Jeffrey A. Weiss, 1011 North Arendell Avenue, P.O. Box 1217, Zebulon, North Carolina 27597–2309, made application to the Drug Enforcement Administration to be registered as an importer of remifentanil (9739), a basic class of controlled substance listed in Schedule II.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Glaxo Wellcome Inc. to import remifentanil is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. Therefore, pursuant to Section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title 21, Code of Federal Regulations, Section 1301.34, the above firm is granted registration as an importer of the basic class of controlled substance listed above.

Dated: July 28, 1997.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 97–21247 Filed 8–11–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By Notice dated April 24, 1997, and published in the **Federal Register** on May 12, 1997, (62 FR 25971), Lipomed, Inc., One Broadway, Cambridge, Massachusetts 02142, made application to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235)	I
Methaqualone (2565)	I
Lysergic acid diethylamide (7315)	I
Tetrahydrocannabinols (7370)	I
Mescaline (7381)	I
3,4,5-Trimethoxyamphetamine (7390).	I
4-Bromo-2, 5-dimethoxyamphetamine (7391).	I
4-Methyl-2, 5-dimethoxyamphetamine (7395).	I
2,5-Dimethoxyamphetamine (7396).	I
2,5-Dimethoxy-4-ethylamphetamine (7399).	I
3,4-Methylenedioxyamphetamine (7400).	I
3,4-Methylenedioxy-N-ethylamphetamine (7404).	I
3,4-Methylenedioxymethamphetamine (7405).	I
Psilocybin (7437)	I
Psilocyn (7438)	I
Acetyldihydrocodeine (9051)	I
Dihydromorphine (9145)	I
Heroin (9200)	I
Tilidine (9750)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Phencyclidine (7471)	II
Cocaine (9041)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Benzoylecgonine (9180)	II
Methadone (9250)	II
Dextropropoxphene, bulk (non-dosage forms) (9273).	II
Morphine (9300)	II
Oxymorphone (9652)	II
Alfentanil (9737)	II
Fentanyl (9801)	II

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Lipomed, Inc. to import the listed controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. Therefore, pursuant to Section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title 21, Code of Federal Regulations, section 1301.34, the above firm is granted registration as an importer of the basic classes of controlled substances listed above.

Dated: July 28, 1997.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 97–21248 Filed 8–11–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated March 31, 1997, and published in the **Federal Register** on May 8, 1997, (62 FR 25210), Lonza Riverside, 900 River Road, Conshohocken, Pennsylvania 19428, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Amphetamine (1100)	II
Phenylacetone (8501)	II

DEA has considered the factors in Title 21, United States Code, section 823(a), as well as information provided by other bulk manufacturers, and